Endologix Acquires Surmodics’ Pounce Thrombectomy System

Endologix announced the acquisition of the Pounce thrombectomy system from Surmodics. The transaction closed on May 18.

The Pounce system is a U.S. Food and Drug Administration (FDA)-cleared mechanical thrombectomy system for non-surgical removal of thrombi and emboli from peripheral arteries. It’s built around proprietary dual-basket technology and a nitinol collection funnel, and is designed to support efficiency, versatility, and efficiency without relying on capital equipment, thrombolytics, or aspiration.

The platform includes Pounce LP, Pounce, and Pounce XL to support use in a range of peripheral arterial vessel sizes, including smaller and more distal vessels. The system will continued marketing in accordance with its existing FDA clearance during a transition period after the acquisition.

This deal bolsters Endologix’s commercial offering for vascular interventionalists already using the company’s Detour, Alto, and AFX2 platforms. Adding a clinically differentiated mechanical thrombectomy option allows the company to support a broader care continuum for patients with peripheral vascular disease.

“The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix,” said John Liddicoat, MD, president and CEO of Endologix. “It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio. We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care.”

A core group of Surmodic team members supporting Pounce will join Endologix as part of the transaction.

“I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense,” said Venkatesh Ramaiah, MD, FACS, Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute. “The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.”